Stanton-Robinson Chayla, Al-Jumaili Ali Azeez, Jackson Amy, Catney Christine, Veach Stevie, Witry Matthew J
J Am Pharm Assoc (2003). 2018 Jul-Aug;58(4S):S120-S124. doi: 10.1016/j.japh.2018.04.030. Epub 2018 Jun 8.
To 1) identify specific patient barriers and pharmacist interventions to medication adherence by means of the Drug Adherence Work-Up (DRAW) tool; and 2) measure patient adherence to antihypertensive and antidiabetic medications by calculating proportion of days covered (PDC) before and after pharmacist telephone adherence interview.
This prospective quality-improvement study consisted of telephonic interviews and targeted interventions to increase medication adherence based on patient-specific barriers. The baseline PDC was electronically calculated for each patient, and postintervention PDCs were manually calculated at 90 days and 180 days after baseline. The measurement period in each PDC calculation was 180 days.
This study was conducted in a small-chain independent pharmacy in rural Midwest United States. Patients taking an antihypertensive or oral antidiabetic medication were identified through an online platform and contacted if they had a PDC of less than 80% during the previous 180 days.
Baseline and postinterview PDC were calculated for each patient who received an adherence interview. Frequency of specific barriers and pharmacist interventions were identified and analyzed.
Ninety-seven eligible patients were identified. Fifty-six patients participated in an interview. Of these, a total of 66 barriers to adherence were identified. Pharmacists implemented 76 interventions for these patients, and 43 patients were included in final PDC calculations. From baseline, 69.0% of patients with hypertension and 64.3% of patients with diabetes reached a PDC of greater than 80% within 3 months. The most frequently identified barrier was forgetfulness on routine days, and the most common interventions were patient education, deactivated drug, and recommend or start medication synchronization program.
Using pharmacists to identify and address patient barriers to adherence resulted in a significant increase in PDC among patients with hypertension and diabetes. The DRAW tool can be used in a community pharmacist-delivered telephonic intervention to improve medication adherence.
1)通过药物依从性检查(DRAW)工具确定影响药物依从性的特定患者障碍和药剂师干预措施;2)通过计算药剂师电话依从性访谈前后的药物覆盖天数比例(PDC)来衡量患者对抗高血压和抗糖尿病药物的依从性。
这项前瞻性质量改进研究包括电话访谈和基于患者特定障碍的针对性干预措施,以提高药物依从性。为每位患者电子计算基线PDC,并在基线后90天和180天手动计算干预后的PDC。每次PDC计算的测量期为180天。
本研究在美国中西部农村的一家小型连锁独立药房进行。通过在线平台识别服用抗高血压或口服抗糖尿病药物的患者,如果他们在过去180天内的PDC低于80%,则与他们联系。
为每位接受依从性访谈的患者计算基线和访谈后的PDC。确定并分析特定障碍和药剂师干预措施的频率。
确定了97名符合条件的患者。56名患者参加了访谈。其中,共确定了66个依从性障碍。药剂师对这些患者实施了76项干预措施,43名患者被纳入最终的PDC计算。从基线开始,69.0%的高血压患者和64.3%的糖尿病患者在三个月内达到了大于80%的PDC。最常识别的障碍是日常健忘,最常见的干预措施是患者教育、停用药物以及推荐或启动药物同步计划。
利用药剂师识别并解决患者的依从性障碍,使高血压和糖尿病患者的PDC显著提高。DRAW工具可用于社区药剂师提供的电话干预,以提高药物依从性。